Company registration number 03505188 (England and Wales)
MALVERN MEDICAL DEVELOPMENTS LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026
PAGES FOR FILING WITH REGISTRAR
MALVERN MEDICAL DEVELOPMENTS LIMITED
COMPANY INFORMATION
Directors
Mr P A Broadbent
Mrs B K Broadbent
Mr P S Broadbent
Secretary
Mr P A Broadbent
Company number
03505188
Registered office
Unit 10
Northbrook Close
Worcester
Worcestershire
WR3 8BP
Accountants
Ormerod Rutter Limited
The Oakley
Kidderminster Road
Droitwich
Worcestershire
WR9 9AY
Bankers
HSBC Bank Plc
6 Broad Street
Worcester
Worcestershire
WR1 3LH
MALVERN MEDICAL DEVELOPMENTS LIMITED
CONTENTS
Page
Accountants' report
1
Balance sheet
2
Notes to the financial statements
3 - 6
MALVERN MEDICAL DEVELOPMENTS LIMITED
ACCOUNTANTS' REPORT TO THE BOARD OF DIRECTORS ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF MALVERN MEDICAL DEVELOPMENTS LIMITED FOR THE YEAR ENDED 31 MARCH 2026
- 1 -

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Malvern Medical Developments Limited for the year ended 31 March 2026 which comprise, the balance sheet and the related notes from the company’s accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at https://www.icaew.com/regulation.

This report is made solely to the b oard of d irectors of Malvern Medical Developments Limited, as a body, in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Malvern Medical Developments Limited and state those matters that we have agreed to state to the b oard of d irectors of Malvern Medical Developments Limited, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Malvern Medical Developments Limited and its b oard of d irectors as a body, for our work or for this report.

It is your duty to ensure that Malvern Medical Developments Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Malvern Medical Developments Limited. You consider that Malvern Medical Developments Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Malvern Medical Developments Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory f inancial statements.

Ormerod Rutter Limited
2 July 2026
Chartered Accountants
The Oakley
Kidderminster Road
Droitwich
Worcestershire
WR9 9AY
MALVERN MEDICAL DEVELOPMENTS LIMITED
BALANCE SHEET
AS AT
31 MARCH 2026
31 March 2026
- 2 -
2026
2025
Notes
£
£
£
£
Fixed assets
Tangible assets
3
6,248
8,635
Current assets
Stocks
225,033
281,467
Debtors
4
161,585
140,452
Cash at bank and in hand
405,152
347,996
791,770
769,915
Creditors: amounts falling due within one year
5
(670,335)
(659,390)
Net current assets
121,435
110,525
Total assets less current liabilities
127,683
119,160
Provisions for liabilities
6
(1,391)
(2,099)
Net assets
126,292
117,061
Capital and reserves
Called up share capital
7
100
100
Profit and loss reserves
126,192
116,961
Total equity
126,292
117,061

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

T he member has not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 2 July 2026 and are signed on its behalf by:
Mr P A Broadbent
Director
Company registration number 03505188 (England and Wales)
MALVERN MEDICAL DEVELOPMENTS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026
- 3 -
1
Accounting policies
Company information

Malvern Medical Developments Limited is a private company limited by shares incorporated in England and Wales. The registered office is Unit 10, Northbrook Close, Worcester, Worcestershire, United Kingdom, WR3 8BP.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods provided in the normal course of business, and is shown net of VAT.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.3
Research and development expenditure

Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Improvements to property
10% on cost
Plant and machinery
20% reducing balance
Fixtures, fittings & equipment
20% reducing balance
Computer equipment
33% on cost
1.5
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

MALVERN MEDICAL DEVELOPMENTS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
1
Accounting policies
(Continued)
- 4 -
1.6
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.7
Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

1.8
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the lease s asset are consumed.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2026
2025
Number
Number
Total
26
27
MALVERN MEDICAL DEVELOPMENTS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
- 5 -
3
Tangible fixed assets
Improvements to property
Plant and machinery
Fixtures, fittings & equipment
Computer equipment
Total
£
£
£
£
£
Cost
At 1 April 2025
115,792
24,848
694
4,734
146,068
Additions
-
0
-
0
280
-
0
280
At 31 March 2026
115,792
24,848
974
4,734
146,348
Depreciation and impairment
At 1 April 2025
115,793
17,791
250
3,599
137,433
Depreciation charged in the year
(1)
1,411
145
1,112
2,667
At 31 March 2026
115,792
19,202
395
4,711
140,100
Carrying amount
At 31 March 2026
-
0
5,646
579
23
6,248
At 31 March 2025
(1)
7,057
444
1,135
8,635
4
Debtors
2026
2025
Amounts falling due within one year:
£
£
Trade debtors
118,104
102,109
Other debtors
43,481
38,343
161,585
140,452
5
Creditors: amounts falling due within one year
2026
2025
£
£
Trade creditors
121,222
126,627
Amounts owed to group undertakings
417,613
371,983
Taxation and social security
100,605
114,081
Other creditors
30,895
46,699
670,335
659,390
6
Provisions for liabilities
2026
2025
£
£
Deferred tax liabilities
1,391
2,099
MALVERN MEDICAL DEVELOPMENTS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026
- 6 -
7
Called up share capital
2026
2025
2026
2025
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary of £1 each
100
100
100
100
8
Related party transactions

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

9
Control

Ultimate parent company

The ultimate parent company is Malvern Medical Group Limited, a company registered in England and Wales.

Ultimate controlling party

The ultimate controlling party is Mr P S Broadbent and Mrs B K Broadbent by virtue of their controlling interest in the ultimate parent company.

2026-03-31 2025-04-01 false false false 02 July 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity Mrs B K Broadbent Mr P S Broadbent Mr P S Broadbent Mr P A Broadbent 03505188 2025-04-01 2026-03-31 03505188 bus:CompanySecretaryDirector1 2025-04-01 2026-03-31 03505188 bus:Director1 2025-04-01 2026-03-31 03505188 bus:Director2 2025-04-01 2026-03-31 03505188 bus:CompanySecretary1 2025-04-01 2026-03-31 03505188 bus:Director3 2025-04-01 2026-03-31 03505188 bus:RegisteredOffice 2025-04-01 2026-03-31 03505188 bus:Agent1 2025-04-01 2026-03-31 03505188 2026-03-31 03505188 2025-03-31 03505188 core:LandBuildings 2026-03-31 03505188 core:PlantMachinery 2026-03-31 03505188 core:FurnitureFittings 2026-03-31 03505188 core:ComputerEquipment 2026-03-31 03505188 core:LandBuildings 2025-03-31 03505188 core:PlantMachinery 2025-03-31 03505188 core:FurnitureFittings 2025-03-31 03505188 core:ComputerEquipment 2025-03-31 03505188 core:CurrentFinancialInstruments core:WithinOneYear 2026-03-31 03505188 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 03505188 core:CurrentFinancialInstruments 2026-03-31 03505188 core:CurrentFinancialInstruments 2025-03-31 03505188 core:ShareCapital 2026-03-31 03505188 core:ShareCapital 2025-03-31 03505188 core:RetainedEarningsAccumulatedLosses 2026-03-31 03505188 core:RetainedEarningsAccumulatedLosses 2025-03-31 03505188 core:ShareCapitalOrdinaryShareClass1 2026-03-31 03505188 core:ShareCapitalOrdinaryShareClass1 2025-03-31 03505188 core:LandBuildings core:LongLeaseholdAssets 2025-04-01 2026-03-31 03505188 core:PlantMachinery 2025-04-01 2026-03-31 03505188 core:FurnitureFittings 2025-04-01 2026-03-31 03505188 core:ComputerEquipment 2025-04-01 2026-03-31 03505188 2024-04-01 2025-03-31 03505188 core:LandBuildings core:LeasedAssetsHeldAsLessee 2025-03-31 03505188 core:PlantMachinery 2025-03-31 03505188 core:FurnitureFittings 2025-03-31 03505188 core:ComputerEquipment 2025-03-31 03505188 2025-03-31 03505188 core:LandBuildings core:LeasedAssetsHeldAsLessee 2026-03-31 03505188 core:LandBuildings core:LeasedAssetsHeldAsLessee 2025-04-01 2026-03-31 03505188 bus:OrdinaryShareClass1 2025-04-01 2026-03-31 03505188 bus:OrdinaryShareClass1 2026-03-31 03505188 bus:OrdinaryShareClass1 2025-03-31 03505188 bus:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 03505188 bus:FRS102 2025-04-01 2026-03-31 03505188 bus:AuditExemptWithAccountantsReport 2025-04-01 2026-03-31 03505188 bus:SmallCompaniesRegimeForAccounts 2025-04-01 2026-03-31 03505188 bus:FullAccounts 2025-04-01 2026-03-31 xbrli:pure xbrli:shares iso4217:GBP